

ADVANCING I-O SCIENCE THROUGH COLLABORATION

Bristol-Myers Squibb has long believed that the **future of cancer research breakthroughs is dependent on investments in science and partnerships.**

Our collaborations with academia, advocacy groups, government, and biotech companies **accelerate our collective ability to address essential scientific questions** in Immuno-Oncology (I-O), helping to facilitate I-O innovation and drug discovery.



The **II-ON** (International Immuno-Oncology Network) is a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to **advance I-O science and translational medicine to improve patient outcomes.**

Launched in 2012, the II-ON was one of the **first networks to bring academia and industry together** to further I-O research.

The II-ON has generated cutting-edge I-O data that have informed the development of new I-O agents, yielded publications and produced some of the earliest findings on a variety of biomarkers and target identification and validation.

THE II-ON PARTNERS COLLABORATE TO:


Generate **innovative** I-O science


Launch **biology-driven** trials


Seek out **cutting-edge** technologies to help translate research into clinical practice

BY THE NUMBERS

350+
investigators

14
clinical trials

190+ research projects

22
tumor types

16
member organizations

THE II-ON'S RESEARCH FOCUSES ON 3 SCIENTIFIC PILLARS:

1

Understanding the mechanisms of resistance to immunotherapy

2

Identifying patient populations likely to benefit from immunotherapy

3

Exploring novel combination therapies that may enhance anti-tumor response through complementary mechanisms of action

MEMBER ORGANIZATIONS

- Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center
- Clinica Universidad Navarra
- Columbia University Medical Center
- Dana-Farber Cancer Institute
- The Earle A. Chiles Research Institute (Providence Health & Services)
- Institut Gustave Roussy
- Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale"

- Memorial Sloan-Kettering Cancer Center
- National Cancer Center Japan
- The Netherlands Cancer Institute
- Peter MacCallum Cancer Center
- The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
- The University of Chicago
- University College London
- West German Cancer Center/University Hospital Essen
- Yale Cancer Center

TO LEARN MORE

about Bristol-Myers Squibb's research partnerships, please visit us at www.bms.com



Bristol-Myers Squibb